JP2019521963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521963A5 JP2019521963A5 JP2018559205A JP2018559205A JP2019521963A5 JP 2019521963 A5 JP2019521963 A5 JP 2019521963A5 JP 2018559205 A JP2018559205 A JP 2018559205A JP 2018559205 A JP2018559205 A JP 2018559205A JP 2019521963 A5 JP2019521963 A5 JP 2019521963A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- inflammation
- composition
- group
- tsp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 claims 8
- 102100023704 Spermatogenic leucine zipper protein 1 Human genes 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 7
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 239000012190 activator Substances 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- 108010017447 4N1K peptide Proteins 0.000 claims 2
- 206010039705 Scleritis Diseases 0.000 claims 2
- 102100021119 Serine protease HTRA1 Human genes 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010015084 Episcleritis Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000007792 Orbital Pseudotumor Diseases 0.000 claims 1
- 208000035452 Orbital pseudotumour Diseases 0.000 claims 1
- 201000001949 Retinal Vasculitis Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 208000038018 age-related macular disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 claims 1
- 201000010668 orbital plasma cell granuloma Diseases 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022035726A JP2022078244A (ja) | 2016-05-10 | 2022-03-08 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2023180474A JP7822577B2 (ja) | 2016-05-10 | 2023-10-19 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169072.2 | 2016-05-10 | ||
| EP16169072 | 2016-05-10 | ||
| EP17154452.1 | 2017-02-02 | ||
| EP17154452 | 2017-02-02 | ||
| PCT/EP2017/061151 WO2017194586A1 (en) | 2016-05-10 | 2017-05-10 | Agents that activate cd47 and their use in the treatment of inflammation |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035726A Division JP2022078244A (ja) | 2016-05-10 | 2022-03-08 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2023180474A Division JP7822577B2 (ja) | 2016-05-10 | 2023-10-19 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521963A JP2019521963A (ja) | 2019-08-08 |
| JP2019521963A5 true JP2019521963A5 (https=) | 2020-05-07 |
| JP7537074B2 JP7537074B2 (ja) | 2024-08-21 |
Family
ID=58772857
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559205A Active JP7537074B2 (ja) | 2016-05-10 | 2017-05-10 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2022035726A Pending JP2022078244A (ja) | 2016-05-10 | 2022-03-08 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2023180474A Active JP7822577B2 (ja) | 2016-05-10 | 2023-10-19 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035726A Pending JP2022078244A (ja) | 2016-05-10 | 2022-03-08 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2023180474A Active JP7822577B2 (ja) | 2016-05-10 | 2023-10-19 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11142548B2 (https=) |
| EP (1) | EP3454884B1 (https=) |
| JP (3) | JP7537074B2 (https=) |
| CA (1) | CA3023802C (https=) |
| WO (1) | WO2017194586A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3023802C (en) * | 2016-05-10 | 2025-02-04 | Inserm (Institut De La Sante Et De La Recherche Medicale) | ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION |
| CN111655253A (zh) | 2018-01-09 | 2020-09-11 | 杨百翰大学 | 用于用汉黄芩素治疗疼痛的组合物和方法 |
| JPWO2022113887A1 (https=) * | 2020-11-27 | 2022-06-02 | ||
| EP4329825A4 (en) * | 2021-04-26 | 2025-03-26 | President and Fellows of Harvard College | CD47 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE EYE DISEASES |
| CN116831988A (zh) * | 2023-06-13 | 2023-10-03 | 南京鼓楼医院 | 一种载肽模拟物pkhb1的脂质体眼用制剂及其制备方法 |
| WO2026062098A1 (fr) | 2024-09-18 | 2026-03-26 | Sorbonne Universite | Nouvelles protéines activatrices de cd47 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US6001962A (en) | 1996-11-15 | 1999-12-14 | The Regents Of The University Of California | Modified Fas ligands |
| CA2226962A1 (en) * | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| EP1087993B1 (en) | 1998-06-18 | 2008-04-02 | Imed Ab | Fas peptides and antibodies for modulating apoptosis |
| EP2479284B1 (en) | 2006-07-13 | 2017-09-20 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
| WO2010070047A1 (en) | 2008-12-19 | 2010-06-24 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| WO2011008495A2 (en) | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
| EP2563359A1 (en) | 2010-04-30 | 2013-03-06 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| US20140127269A1 (en) | 2012-02-13 | 2014-05-08 | The Schepens Eye Research Institute, Inc. | Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof |
| EP3434276B1 (en) | 2012-06-06 | 2024-10-30 | Pepkon | Method and pharmaceutical composition for use in the treatment of cancer |
| US10004780B2 (en) | 2012-10-17 | 2018-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD) |
| US10113169B2 (en) | 2013-12-23 | 2018-10-30 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for treating cancer using peptide nucleic acid-based agents |
| EP2898896A1 (en) * | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| EP3193933B1 (en) | 2014-09-17 | 2021-04-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd276 antibodies (b7h3) |
| US10016480B2 (en) | 2014-10-14 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Peptide-based methods for treating pancreatic cancer |
| FR3036620B1 (fr) * | 2015-05-27 | 2017-09-01 | Inst Biophytis | Utilisation de 3-desoxyanthocyanidines pour le traitement de maladies oculaires |
| CA3023802C (en) * | 2016-05-10 | 2025-02-04 | Inserm (Institut De La Sante Et De La Recherche Medicale) | ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION |
-
2017
- 2017-05-10 CA CA3023802A patent/CA3023802C/en active Active
- 2017-05-10 EP EP17725893.6A patent/EP3454884B1/en active Active
- 2017-05-10 WO PCT/EP2017/061151 patent/WO2017194586A1/en not_active Ceased
- 2017-05-10 US US16/300,438 patent/US11142548B2/en active Active
- 2017-05-10 JP JP2018559205A patent/JP7537074B2/ja active Active
-
2022
- 2022-03-08 JP JP2022035726A patent/JP2022078244A/ja active Pending
-
2023
- 2023-10-19 JP JP2023180474A patent/JP7822577B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521963A5 (https=) | ||
| JP2016510728A5 (https=) | ||
| JP6086067B2 (ja) | Ｇｉｐレセプター活性を示すグルカゴンアナローグ | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| CN104583233B (zh) | 表现出gip受体活性的胰高血糖素的类似物 | |
| JP2018538356A5 (https=) | ||
| JP2017528419A5 (https=) | ||
| WO2011094337A1 (en) | Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity | |
| JP2018515088A5 (https=) | ||
| JP2017500018A5 (https=) | ||
| WO2014152460A2 (en) | Prodrugs with prolonged action | |
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| JP2019507589A5 (https=) | ||
| JP2017527272A5 (https=) | ||
| JP2023179752A5 (https=) | ||
| JP2019533722A5 (https=) | ||
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2016536357A5 (https=) | ||
| WO2015138604A1 (en) | Compositions and methods for treating eye infections and disease | |
| MX2025001402A (es) | Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| WO2006087550A3 (en) | Amyloid-binding peptides, analogues and uses thereof | |
| KR20220143702A (ko) | Ras 단백질을 표적화하는 분자 | |
| JP2019038772A5 (https=) | ||
| WO2018156892A1 (en) | Peptide inhibitors of transcription factor aggregation |